title: Antimouse antibody response after OKT3 administration for steroid resistant rejection.
abstract: OKT3 has become one of the more effective antirejection therapies for patients receiving kidney transplants. However, its usefulness is diminished or blocked by the development of antimouse/anti-OKT3 antibodies. We evaluated 17 children receiving OKT3 for steroid-resistant acute rejection for the development and persistence of antibodies after therapy. OKT3 was successful in reversing acute rejection in 14 of 17 patients. Eight children developed antimouse antibodies, 7 at a low titer (1:100). The retesting of all children 6 months later showed no detectable antibodies. Children develop anti-OKT3 antibodies at a rate similar to adults and with time lose detectable levels which may have significance if a subsequent course of OKT3 is needed.
authors.affiliation: St. Christopher's Hospital for Children, Department of Pediatrics, Temple University School of Medicine, Philadelphia, Pa.
authors.forename: B A
authors.initials: BA
authors.lastname: Kaiser
authors.forename: J A
authors.initials: JA
authors.lastname: Palmer
authors.forename: S P
authors.initials: SP
authors.lastname: Dunn
authors.forename: M A
authors.initials: MA
authors.lastname: Mochon
authors.forename: S M
authors.initials: SM
authors.lastname: Bartosh
authors.forename: S L
authors.initials: SL
authors.lastname: Schulman
authors.forename: M S
authors.initials: MS
authors.lastname: Polinsky
authors.forename: H J
authors.initials: HJ
authors.lastname: Baluarte
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology*; D002648:Child; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D051379:Mice / Q000276:immunology*; D016853:Muromonab-CD3 / Q000276:immunology* / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D000906:Antibodies; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D008775:Methylprednisolone